US StockDetailed Quotes

Provided by Tiger Trade Technology Pte. Ltd.

Aardvark Therapeutics

5.44

-0.1600-2.86%

Post-market: 5.30-0.1400-2.57%18:42 EDT

Volume:84.00K

Turnover:458.04K

Market Cap:118.03M

PE:-2.06

High:5.65

Open:5.64

Low:5.30

Close:5.60

52wk High:17.94

52wk Low:3.35

Shares:21.70M

Float Shares:5.89M

Volume Ratio:0.77

T/O Rate:1.43%

Dividend:- -

Dividend Rate:- -

EPS(TTM):-2.6398

EPS(LYR):-0.7400

ROE:-58.79%

ROA:-36.54%

PB:1.36

PE(LYR):-7.35

Loading ...

Overview Company News Filings

RBC Capital Reaffirms Their Hold Rating on Aardvark Therapeutics, Inc. (AARD)

Aardvark Therapeutics reports Q1 EPS (99c), consensus (91c)

Aardvark Therapeutics Q1 EPS $(0.99) Misses $(0.90) Estimate

Aardvark Q1 net loss widens to $21.6 million; R&D expenses rise to $16.6 million

Aardvark Therapeutics Inc Q1 Operating Expenses USD 22.464 Million

THOMSON REUTERS

Aardvark Therapeutics Inc Q1 Income From Operations USD -22.464 Million

THOMSON REUTERS

Aardvark Therapeutics Inc Q1 Net Income USD -21.588 Million VS. Ibes Estimate USD -18.3 Million

THOMSON REUTERS

Press Release: Aardvark Therapeutics Reports First Quarter 2026 Financial Results and Provides Business Updates

U.S. RESEARCH ROUNDUP-Amazon, Diamondback Energy, Matador Resources

Aardvark Therapeutics Inc : B. Riley Cuts Target Price to $8 From $32

THOMSON REUTERS

B. Riley Adjusts Aardvark Therapeutics Price Target to $8 From $32, Maintains Buy Rating

MT Newswires Live

RBC Capital Sticks to Its Hold Rating for Aardvark Therapeutics, Inc. (AARD)

Aardvark Therapeutics Price Target Maintained With a $9.00/Share by BTIG

Aardvark Therapeutics Establishes $150 Million Equity Program

Aardvark Therapeutics Inc - Enters Equity Distribution Agreement With Piper Sandler on March 23, 2026 - SEC Filing

THOMSON REUTERS

Aardvark Therapeutics Inc - May Offer Shares up to $150 Mln Aggregate Offering Price - SEC Filing

THOMSON REUTERS

Aardvark Therapeutics signs equity distribution agreement for up to USD 150 million offering

Aardvark pauses two obesity drug trials as it reviews side effects

Aardvark Therapeutics Files $400 Million Mixed Shelf

MT Newswires Live

Aardvark Therapeutics files $400M mixed securities shelf

{"basename":"","ssrTDKData":{"titleTemplate":"%s - Tiger Brokers","title":"Tiger Brokers | Global Stocks, Options & Futures Trading App","description":"Tiger Brokers, one-stop investment in US stocks, SGX stocks, HK stocks, A-shares & other global assets. One of the best stock trading platforms in Singapore.","keywords":"tiger brokers,tiger trade,tiger brokers singapore,broker online,stock trading in singapore,share trading singapore,brokerage firm singapore,trading app,stock broker singapore,stock trading platforms,trading account","social":{"ogDescription":"Tiger Brokers, one-stop investment in US stocks, SGX stocks, HK stocks, A-shares & other global assets. One of the best stock trading platforms in Singapore.","ogImage":"https://c1.itigergrowtha.com/portal5/static/media/og-logo.be62fbe1.png","ogUrl":"https://www.itiger.com/stock/AARD/news"},"companyName":"Tiger Brokers"},"pageData":{"isMobile":false,"isTiger":false,"isTTM":true,"region":"SGP","license":"TBSG","edition":"fundamental","symbol":"AARD","isAnalysisPage":false},"__swrFallback__":{"@#url:\"https://hq.skytigris.cn/stock_info/detail/global\",params:#delay:false,,method:\"POST\",data:#items:@#symbol:\"AARD\",,,,,undefined,":{"symbol":"AARD","market":"US","secType":"STK","nameCN":"Aardvark Therapeutics","latestPrice":5.44,"timestamp":1778270400000,"preClose":5.6,"halted":0,"volume":84002,"hourTrading":{"tag":"盘后","latestPrice":5.3,"preClose":5.44,"latestTime":"18:42 EDT","volume":11552,"amount":63214.72,"timestamp":1778280158434,"change":-0.14,"changeRate":-0.025735,"amplitude":0.064338},"delay":0,"changeRate":-0.02857142857142844,"floatShares":5888000,"shares":21696893,"eps":-2.6398466,"marketStatus":"Market Closed","change":-0.16,"latestTime":"05-08 16:00:00 EDT","open":5.64,"high":5.65,"low":5.3003,"amount":458044.047551,"amplitude":0.062446,"askPrice":0,"askSize":0,"bidPrice":0,"bidSize":0,"shortable":3,"etf":0,"ttmEps":-2.6398466,"tradingStatus":0,"nextMarketStatus":{"tag":"Pre-Mkt","tradingStatus":1,"beginTime":1778486400000},"marketStatusCode":7,"adr":0,"listingDate":1739509200000,"exchange":"NASDAQ","adjPreClose":5.6,"preHourTrading":{"tag":"盘前","latestPrice":5.6,"preClose":5.6,"latestTime":"04:01 EDT","volume":7,"amount":39.199999999999996,"timestamp":1778227300177,"change":0,"changeRate":0,"amplitude":0},"postHourTrading":{"tag":"盘后","latestPrice":5.3,"preClose":5.44,"latestTime":"18:42 EDT","volume":11552,"amount":63214.72,"timestamp":1778280158434,"change":-0.14,"changeRate":-0.025735,"amplitude":0.064338},"volumeRatio":0.7692427425538001,"impliedVol":4.9543,"impliedVolPercentile":0.9867},"@#url:\"https://hq.skytigris.cn/stock_info/fundamental/all\",params:#delay:false,,method:\"POST\",data:#items:@#symbol:\"AARD\",,,,,undefined,":{"symbol":"AARD","floatShares":5888000,"roa":"-36.54%","roe":"-58.79%","lyrEps":-0.74,"volumeRatio":0.7692427425538001,"shares":21696893,"dividePrice":0,"high":5.65,"amplitude":0.062446,"preClose":5.6,"low":5.3003,"week52Low":3.35,"pbRate":"1.36","week52High":17.94,"institutionHeld":0,"latestPrice":5.44,"eps":-2.6398466,"divideRate":0,"volume":84002,"delay":0,"ttmEps":-2.6398466,"open":5.64,"prevYearClose":13.125,"prevWeekClose":5.46,"prevMonthClose":5.43,"prevQuarterClose":3.77,"fiveDayClose":5.46,"twentyDayClose":3.94,"sixtyDayClose":12.67},"@#url:\"https://hq.skytigris.cn/fundamental/corporate_actions/details/AARD\",params:#limit:5,,,undefined,":[{"market":"US","date":"2026-03-23","symbol":"AARD","fiscalQuarterEnding":"2025/12","expectedEps":-0.81,"name":null,"time":"Post Market","type":"earning","dateTimestamp":1774238400000,"reportTimeType":"post","actualEps":-0.81},{"market":"US","date":"2025-11-13","symbol":"AARD","fiscalQuarterEnding":"2025/09","expectedEps":-0.82,"name":null,"time":"Post Market","type":"earning","dateTimestamp":1763010000000,"reportTimeType":"post","actualEps":-0.75},{"market":"US","date":"2025-08-13","symbol":"AARD","fiscalQuarterEnding":"2025/06","expectedEps":-0.52,"name":null,"time":"Post Market","type":"earning","dateTimestamp":1755057600000,"reportTimeType":"post","actualEps":-0.66},{"market":"US","date":"2025-05-14","symbol":"AARD","fiscalQuarterEnding":"2025/03","expectedEps":-0.7,"name":null,"time":"Post Market","type":"earning","dateTimestamp":1747195200000,"reportTimeType":"post","actualEps":-0.71},{"market":"US","date":"2025-03-31","symbol":"AARD","fiscalQuarterEnding":null,"expectedEps":null,"name":null,"time":"Post Market","type":"earning","dateTimestamp":1743393600000,"reportTimeType":"post","actualEps":null}],"@#url:\"https://hq.skytigris.cn/fundamental/dividend/history\",params:#symbol:\"AARD\",market:\"US\",,,undefined,":[],"@#url:\"https://hq.skytigris.cn/fundamental/estimate/recommendation\",params:#symbol:\"AARD\",market:\"US\",delay:false,,,undefined,":{},"@#url:\"https://hq.skytigris.cn/value_analysis/stock/AARD\",params:#withQuantilePoint:true,period:\"5year\",factor:\"peRate\",delay:false,algorithm:1,,,undefined,":{"brief":{"id":"AARD","date":"2026-05-07","current":-2.060726,"percent":0.885621,"low":-51.17654,"twenty":-10.13485,"median":-6.732161,"eighty":-4.75889,"high":-1.329623,"avg":-9.279559,"sd":8.698329,"marketCap":128496481},"quantilePoints":[{"date":"2025-02-21","current":-51.17654,"twenty":-46.993414,"median":-42.216938,"eighty":-39.920668,"marketCap":368880503},{"date":"2025-02-28","current":-39.75453,"twenty":-42.139802,"median":-40.229211,"eighty":-39.232381,"marketCap":286550651},{"date":"2025-03-07","current":-28.243517,"twenty":-40.603022,"median":-39.176012,"eighty":-36.900511,"marketCap":203579269},{"date":"2025-03-14","current":-31.091602,"twenty":-40.336014,"median":-37.766803,"eighty":-30.723725,"marketCap":224108270},{"date":"2025-03-21","current":-27.23482,"twenty":-39.944402,"median":-34.681377,"eighty":-29.198812,"marketCap":196308580},{"date":"2025-03-28","current":-26.404128,"twenty":-39.576524,"median":-30.913597,"eighty":-27.946841,"marketCap":190320955},{"date":"2025-04-04","current":-9.026143,"twenty":-39.119644,"median":-30.068072,"eighty":-27.341623,"marketCap":185830236},{"date":"2025-04-11","current":-7.397773,"twenty":-38.751766,"median":-29.400552,"eighty":-17.252871,"marketCap":152305358},{"date":"2025-04-17","current":-7.977371,"twenty":-38.300819,"median":-28.45119,"eighty":-8.603741,"marketCap":164238114},{"date":"2025-04-25","current":-8.66235,"twenty":-37.766803,"median":-27.946841,"eighty":-8.371497,"marketCap":178340462},{"date":"2025-05-02","current":-11.939711,"twenty":-36.900511,"median":-27.412825,"eighty":-8.371497,"marketCap":245814773},{"date":"2025-05-09","current":-11.307423,"twenty":-34.865316,"median":-26.68597,"eighty":-8.46634,"marketCap":232797221},{"date":"2025-05-16","current":-7.114571,"twenty":-32.693651,"median":-13.552046,"eighty":-8.46634,"marketCap":197215912},{"date":"2025-05-23","current":-7.834638,"twenty":-31.0204,"median":-11.823792,"eighty":-8.360959,"marketCap":217176159},{"date":"2025-05-30","current":-8.061615,"twenty":-30.818661,"median":-11.433881,"eighty":-8.172533,"marketCap":223467976},{"date":"2025-06-06","current":-9.353039,"twenty":-30.367714,"median":-11.107198,"eighty":-8.178795,"marketCap":259266244},{"date":"2025-06-13","current":-8.656453,"twenty":-30.076972,"median":-10.833207,"eighty":-8.210998,"marketCap":239956875},{"date":"2025-06-20","current":-9.454788,"twenty":-30.053238,"median":-10.188135,"eighty":-8.218152,"marketCap":262086713},{"date":"2025-06-27","current":-10.84796,"twenty":-29.697227,"median":-10.664596,"eighty":-8.356744,"marketCap":300705451},{"date":"2025-07-03","current":-10.894921,"twenty":-29.459887,"median":-10.613156,"eighty":-8.365174,"marketCap":302007206},{"date":"2025-07-11","current":-9.861782,"twenty":-29.308323,"median":-10.597502,"eighty":-8.375712,"marketCap":273368592},{"date":"2025-07-18","current":-9.360866,"twenty":-28.618005,"median":-10.433139,"eighty":-8.40036,"marketCap":259483203},{"date":"2025-07-25","current":-10.542714,"twenty":-28.285052,"median":-10.45662,"eighty":-8.474871,"marketCap":292244042},{"date":"2025-08-01","current":-9.4,"twenty":-28.006176,"median":-10.433139,"eighty":-8.577715,"marketCap":260567999},{"date":"2025-08-08","current":-9.368693,"twenty":-27.946841,"median":-10.061366,"eighty":-8.607418,"marketCap":259700162},{"date":"2025-08-15","current":-6.668132,"twenty":-27.567096,"median":-9.861782,"eighty":-8.474871,"marketCap":244307015},{"date":"2025-08-22","current":-5.762071,"twenty":-27.424692,"median":-9.803081,"eighty":-8.329026,"marketCap":211110768},{"date":"2025-08-29","current":-5.027748,"twenty":-27.270421,"median":-9.525229,"eighty":-8.145134,"marketCap":184206621},{"date":"2025-09-05","current":-5.027748,"twenty":-27.074615,"median":-9.478268,"eighty":-8.014507,"marketCap":184206621},{"date":"2025-09-12","current":-4.61321,"twenty":-26.629602,"median":-9.396086,"eighty":-7.797069,"marketCap":169018796},{"date":"2025-09-19","current":-6.685898,"twenty":-23.929853,"median":-9.368693,"eighty":-7.515801,"marketCap":244957921},{"date":"2025-09-26","current":-7.503129,"twenty":-17.043362,"median":-9.298251,"eighty":-7.308831,"marketCap":274899634},{"date":"2025-10-03","current":-9.102059,"twenty":-12.821851,"median":-9.210333,"eighty":-7.389343,"marketCap":333481245},{"date":"2025-10-10","current":-9.824539,"twenty":-12.161077,"median":-9.298251,"eighty":-7.460987,"marketCap":359951454},{"date":"2025-10-17","current":-7.876213,"twenty":-12.040618,"median":-9.212156,"eighty":-7.503145,"marketCap":288568676},{"date":"2025-10-24","current":-6.425331,"twenty":-11.978881,"median":-9.149542,"eighty":-7.334887,"marketCap":235411289},{"date":"2025-10-31","current":-6.194375,"twenty":-11.800608,"median":-9.102059,"eighty":-7.096882,"marketCap":226949500},{"date":"2025-11-07","current":-5.844979,"twenty":-11.619352,"median":-9.083015,"eighty":-6.739195,"marketCap":214148333},{"date":"2025-11-14","current":-6.453893,"twenty":-11.527382,"median":-8.978494,"eighty":-6.599437,"marketCap":236457733},{"date":"2025-11-21","current":-4.209833,"twenty":-11.386619,"median":-8.807467,"eighty":-6.451943,"marketCap":205321954},{"date":"2025-11-28","current":-4.455369,"twenty":-11.26527,"median":-8.719067,"eighty":-6.366112,"marketCap":217297254},{"date":"2025-12-05","current":-5.535729,"twenty":-11.176245,"median":-8.71121,"eighty":-6.20385,"marketCap":269988572},{"date":"2025-12-12","current":-6.968768,"twenty":-11.12541,"median":-8.663092,"eighty":-6.182531,"marketCap":339880775},{"date":"2025-12-19","current":-6.111623,"twenty":-11.06083,"median":-8.610671,"eighty":-6.174808,"marketCap":298076093},{"date":"2025-12-26","current":-6.366088,"twenty":-10.989171,"median":-8.599121,"eighty":-6.172233,"marketCap":310486858},{"date":"2026-01-02","current":-5.859391,"twenty":-10.980741,"median":-8.405995,"eighty":-6.111623,"marketCap":285774195},{"date":"2026-01-09","current":-6.477696,"twenty":-10.894921,"median":-8.362013,"eighty":-6.093766,"marketCap":315930176},{"date":"2026-01-16","current":-6.852697,"twenty":-10.894921,"median":-8.218152,"eighty":-6.111623,"marketCap":334219725},{"date":"2026-01-23","current":-6.732161,"twenty":-10.894921,"median":-8.171191,"eighty":-6.111623,"marketCap":328340941},{"date":"2026-01-30","current":-5.959837,"twenty":-10.857352,"median":-8.086731,"eighty":-6.108052,"marketCap":290673181},{"date":"2026-02-06","current":-5.040192,"twenty":-10.779084,"median":-8.030062,"eighty":-6.020346,"marketCap":245820240},{"date":"2026-02-13","current":-5.482157,"twenty":-10.700911,"median":-7.926792,"eighty":-5.956266,"marketCap":267375780},{"date":"2026-02-20","current":-5.540193,"twenty":-10.673027,"median":-7.864204,"eighty":-5.92323,"marketCap":270206305},{"date":"2026-02-27","current":-5.580372,"twenty":-10.643124,"median":-7.834638,"eighty":-5.890776,"marketCap":272165900},{"date":"2026-03-06","current":-2.562507,"twenty":-10.619417,"median":-7.684115,"eighty":-5.801764,"marketCap":124978581},{"date":"2026-03-13","current":-2.34822,"twenty":-10.594371,"median":-7.524231,"eighty":-5.747859,"marketCap":114527410},{"date":"2026-03-20","current":-2.187506,"twenty":-10.558368,"median":-7.450451,"eighty":-5.647336,"marketCap":106689032},{"date":"2026-03-27","current":-1.329623,"twenty":-10.505146,"median":-7.272172,"eighty":-5.612515,"marketCap":76574303},{"date":"2026-04-02","current":-1.549332,"twenty":-10.461316,"median":-7.114571,"eighty":-5.565193,"marketCap":89227607},{"date":"2026-04-10","current":-1.477359,"twenty":-10.383939,"median":-7.072594,"eighty":-5.510729,"marketCap":85082559},{"date":"2026-04-17","current":-1.890261,"twenty":-10.268548,"median":-6.92859,"eighty":-5.336927,"marketCap":108862044},{"date":"2026-04-24","current":-2.034209,"twenty":-10.187377,"median":-6.86609,"eighty":-5.089336,"marketCap":117152140},{"date":"2026-05-01","current":-2.056938,"twenty":-10.153251,"median":-6.792493,"eighty":-4.960237,"marketCap":118461102},{"date":"2026-05-07","current":-2.23119,"twenty":-10.13485,"median":-6.732161,"eighty":-4.75889,"marketCap":128496481}],"updateTime":1778314702976},"$inf$@#url:\"https://stock-news.skytigris.cn/v2/news/list\",params:#symbols:\"AARD\",pageSize:20,pageCount:1,lang_content:\"en\",edition:\"fundamental\",,,undefined,":[{"items":[{"id":"2634949646","title":"RBC Capital Reaffirms Their Hold Rating on Aardvark Therapeutics, Inc. (AARD)","url":"https://stock-news.laohu8.com/highlight/detail?id=2634949646","media":"TIPRANKS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2634949646?lang=en_us&edition=fundamental","pubTime":"2026-05-09 09:55","pubTimestamp":1778291709,"startTime":"0","endTime":"0","summary":"RBC Capital analyst Brian Abrahams maintained a Hold rating on Aardvark Therapeutics, Inc. on May 7 and set a price target of $6.00. The company’s ...","market":"nz","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tipranks_highlight","url":"https://www.tipranks.com/news/blurbs/rbc-capital-reaffirms-their-hold-rating-on-aardvark-therapeutics-inc-aard-blurbs-news?utm_source=itigerup.com&utm_medium=referral","rn_cache_url":null,"directOrigin":true},"property":["rate"],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.tipranks.com/news/blurbs/rbc-capital-reaffirms-their-hold-rating-on-aardvark-therapeutics-inc-aard-blurbs-news?utm_source=itigerup.com&utm_medium=referral","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"tipranks_highlight","symbols":["AARD"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2633173903","title":"Aardvark Therapeutics reports Q1 EPS (99c), consensus (91c)","url":"https://stock-news.laohu8.com/highlight/detail?id=2633173903","media":"TIPRANKS","labels":["dataReport"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2633173903?lang=en_us&edition=fundamental","pubTime":"2026-05-08 03:19","pubTimestamp":1778181563,"startTime":"0","endTime":"0","summary":"“We have been working closely with the FDA to comprehensively evaluate the data following the reversible cardiac observations in the healthy volunt...","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tipranks_highlight","url":"https://www.tipranks.com/news/the-fly/aardvark-therapeutics-reports-q1-eps-99c-consensus-91c-thefly-news?utm_source=itigerup.com&utm_medium=referral","rn_cache_url":null,"directOrigin":true},"property":["earning"],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.tipranks.com/news/the-fly/aardvark-therapeutics-reports-q1-eps-99c-consensus-91c-thefly-news?utm_source=itigerup.com&utm_medium=referral","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"dataReport","news_rank":0,"length":0,"strategy_id":0,"source":"tipranks_highlight","symbols":["AARD"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2633314447","title":"Aardvark Therapeutics Q1 EPS $(0.99) Misses $(0.90) Estimate","url":"https://stock-news.laohu8.com/highlight/detail?id=2633314447","media":"Benzinga","labels":["express"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2633314447?lang=en_us&edition=fundamental","pubTime":"2026-05-07 20:12","pubTimestamp":1778155943,"startTime":"0","endTime":"0","summary":"Aardvark Therapeutics (NASDAQ:AARD) reported quarterly losses of $(0.99) per share which missed the analyst consensus estimate of $(0.90) by 10 percent. This is a 39.44 percent decrease over losses of $(0.71) per share","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":["earning"],"language":"en","translate_title":"","themeId":"11c8fbbf839f433c9d274cef5f173382","theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.benzinga.com/news/earnings/26/05/52363310/aardvark-therapeutics-q1-eps-0-99-misses-0-90-estimate","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-1","news_top_title":null,"news_tag":"express","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["AARD"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2633144161","title":"Aardvark Q1 net loss widens to $21.6 million; R&D expenses rise to $16.6 million","url":"https://stock-news.laohu8.com/highlight/detail?id=2633144161","media":"Reuters","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2633144161?lang=en_us&edition=fundamental","pubTime":"2026-05-07 20:09","pubTimestamp":1778155749,"startTime":"0","endTime":"0","summary":"Aardvark Therapeutics posted a Q1 net loss of USD 21.6 million, widening from USD 9.3 million a year earlier; R&D expense climbed to USD 16.6 million from USD 7.8 million.G&A expense rose to USD 5.9 million from USD 2.7 million.Cash, cash equivalents and short-term investments fell to USD 91.2 million as of March 31 from USD 110 million at year-end; runway projected into mid-2027.Enrollment and dosing remain voluntarily paused in Phase 3 HERO and OLE trials of lead candidate ARD-101 following unexpected reversible cardiac observations in a separate healthy-volunteer study; further guidance expected in Q2 2026.Development of ARD-201 was also voluntarily paused in March; CEO Tien Lee said the company is working with FDA to evaluate data and establish a path forward for the ARD-101 program.","market":"nz","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260507:nNDL80mh3n:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["SG9999014013.SGD","IE00BGHQF748.EUR","BK4112","BK4588","IE00BN0W2V16.EUR","IE00B64PRP62.GBP","SG9999014039.USD","IE00B3QW5Z07.USD","BK4585","LU2210150020.SGD","LU2095319765.USD","LU2210149790.SGD","AARD","IE00BKPKM429.USD","NDAQ","BK4007","SG9999014021.USD","SG9999014005.SGD","IE00BN0W2T93.GBP","IE00BN0W2W23.USD","LU0314104364.USD"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2633210141","title":"Aardvark Therapeutics Inc Q1 Operating Expenses USD 22.464 Million","url":"https://stock-news.laohu8.com/highlight/detail?id=2633210141","media":"THOMSON REUTERS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2633210141?lang=en_us&edition=fundamental","pubTime":"2026-05-07 20:00","pubTimestamp":1778155204,"startTime":"0","endTime":"0","summary":null,"market":"nz","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260507:nPLXDB9F15:3","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"reuters_en_live","symbols":["AARD","BK4007"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2633141763","title":"Aardvark Therapeutics Inc Q1 Income From Operations USD -22.464 Million","url":"https://stock-news.laohu8.com/highlight/detail?id=2633141763","media":"THOMSON REUTERS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2633141763?lang=en_us&edition=fundamental","pubTime":"2026-05-07 20:00","pubTimestamp":1778155204,"startTime":"0","endTime":"0","summary":null,"market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260507:nPLXDB9F15:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"reuters_en_live","symbols":["AARD","BK4007"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2633141211","title":"Aardvark Therapeutics Inc Q1 Net Income USD -21.588 Million VS. Ibes Estimate USD -18.3 Million","url":"https://stock-news.laohu8.com/highlight/detail?id=2633141211","media":"THOMSON REUTERS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2633141211?lang=en_us&edition=fundamental","pubTime":"2026-05-07 20:00","pubTimestamp":1778155204,"startTime":"0","endTime":"0","summary":null,"market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260507:nPLXDB9F15:2","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"reuters_en_live","symbols":["AARD","BK4007"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2633410771","title":"Press Release: Aardvark Therapeutics Reports First Quarter 2026 Financial Results and Provides Business Updates","url":"https://stock-news.laohu8.com/highlight/detail?id=2633410771","media":"Dow Jones","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2633410771?lang=en_us&edition=fundamental","pubTime":"2026-05-07 20:00","pubTimestamp":1778155200,"startTime":"0","endTime":"0","summary":"ARD-101 and ARD-201 programs on voluntary pause; further guidance expected in Q2 2026. $91.2 million in cash, cash equivalents and short-term investments as of March 31, 2026, supports projected operations into mid-2027. SAN DIEGO, May 07, 2026  -- Aardvark Therapeutics, Inc.  , a clinical-stage biopharmaceutical company focused on developing novel, small-molecule therapeutics to activate innate homeostatic pathways for the treatment of metabolic diseases, today reported financial results for the first quarter ended March 31, 2026, and provided pipeline and business updates.\"We have been working closely with the FDA to comprehensively evaluate the data following the reversible cardiac observations in the healthy volunteer trial and are committed to determining the best path forward for our programs, patients and the broader PWS community,\" said Tien Lee, M.D., Founder and Chief Executive Officer of Aardvark. \"We remain focused on establishing a clear path forward for the Phase 3 HERO t","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://dowjonesnews.com/newdjn/logon.aspx?AL=N","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["LU0054578231.USD","LU0708994859.HKD","LU1267930573.SGD","LU0211328371.USD","LU1803068623.USD","LU1267930490.SGD","BK4126","LU1989763690.USD","LU0310799852.SGD","LU0029874061.USD","LU1989763427.SGD","BK4007","LU1892829315.USD","LU0211327993.USD","LU0029864427.USD","CCK","HERO","LU0128525929.USD","PWS","LU0128526141.USD","LU0310800379.SGD","AARD"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2622023931","title":"U.S. RESEARCH ROUNDUP-Amazon, Diamondback Energy, Matador Resources","url":"https://stock-news.laohu8.com/highlight/detail?id=2622023931","media":"Reuters","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2622023931?lang=en_us&edition=fundamental","pubTime":"2026-03-25 16:01","pubTimestamp":1774425680,"startTime":"0","endTime":"0","summary":"U.S. RESEARCH ROUNDUP-Amazon, Diamondback Energy, Matador ResourcesMarch 25 (Reuters) - Wall Street securities analysts revised their ratings and price targets on several U.S.-listed companies on Wedn","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":"ab6e84fb0542480d9cf75cb6a9fe5601","theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260325:nL8N40D0JI:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["ESE","EVGO","DG","FANG","CALM","BZAI","BAM","ACAD","AARD","ABSI","CVI","FIG","DK","FRPT","GLW","AMZN","GENB","ARE","BP","CNM","APEI","KBH","AVTX","AMZP","BXP","AFG","AMZU","AMZD","INSM","BPH","AZYY","BTM","AIR","BRZE","CEG","ELVN","MTDR","CEGX","AVAH","DINO","HD","BWXT","CVX","USAW.SI","CDE","ADUS","HAL","BCAX","FIGG"],"isVideo":false,"video":null,"gpt_icon":1},{"id":"2621206244","title":"Aardvark Therapeutics Inc : B. Riley Cuts Target Price to $8 From $32","url":"https://stock-news.laohu8.com/highlight/detail?id=2621206244","media":"THOMSON REUTERS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2621206244?lang=en_us&edition=fundamental","pubTime":"2026-03-24 20:40","pubTimestamp":1774356009,"startTime":"0","endTime":"0","summary":null,"market":"nz","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260324:nFWN40C0A0:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"reuters_en_live","symbols":["BK4007","AARD"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2621062681","title":"B. Riley Adjusts Aardvark Therapeutics Price Target to $8 From $32, Maintains Buy Rating","url":"https://stock-news.laohu8.com/highlight/detail?id=2621062681","media":"MT Newswires Live","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2621062681?lang=en_us&edition=fundamental","pubTime":"2026-03-24 20:30","pubTimestamp":1774355441,"startTime":"0","endTime":"0","summary":"B. Riley Adjusts Aardvark Therapeutics Price Target to $8 From $32, Maintains Buy Rating","market":"sh","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":["rate"],"language":"en","translate_title":"","themeId":"f6f7c9f6a0174df79daf9f1dfd21f836","theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.mtnewswires.com/","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"mtnewswires_news","symbols":["AARD"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2621061633","title":"RBC Capital Sticks to Its Hold Rating for Aardvark Therapeutics, Inc. (AARD)","url":"https://stock-news.laohu8.com/highlight/detail?id=2621061633","media":"TIPRANKS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2621061633?lang=en_us&edition=fundamental","pubTime":"2026-03-24 19:36","pubTimestamp":1774352171,"startTime":"0","endTime":"0","summary":"RBC Capital analyst Brian Abrahams maintained a Hold rating on Aardvark Therapeutics, Inc. yesterday and set a price target of $6.00. The company’s...","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tipranks_highlight","url":"https://www.tipranks.com/news/blurbs/rbc-capital-sticks-to-its-hold-rating-for-aardvark-therapeutics-inc-aard-blurbs-news?utm_source=itigerup.com&utm_medium=referral","rn_cache_url":null,"directOrigin":true},"property":["rate"],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.tipranks.com/news/blurbs/rbc-capital-sticks-to-its-hold-rating-for-aardvark-therapeutics-inc-aard-blurbs-news?utm_source=itigerup.com&utm_medium=referral","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"tipranks_highlight","symbols":["AARD"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2621069396","title":"Aardvark Therapeutics Price Target Maintained With a $9.00/Share by BTIG","url":"https://stock-news.laohu8.com/highlight/detail?id=2621069396","media":"Dow Jones","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2621069396?lang=en_us&edition=fundamental","pubTime":"2026-03-24 19:09","pubTimestamp":1774350540,"startTime":"0","endTime":"0","summary":"Ratings actions from Benzinga: https://www.benzinga.com/quote/AARD/analyst-ratings \n\n\n \n\n\n  (END) Dow Jones Newswires\n\n\n  March 24, 2026 07:09 ET (11:09 GMT)","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":["rate"],"language":"en","translate_title":"","themeId":"8603dabb40994e59ac78c04c930c0d49","theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://dowjonesnews.com/newdjn/logon.aspx?AL=N","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["AARD"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2621065739","title":"Aardvark Therapeutics Establishes $150 Million Equity Program","url":"https://stock-news.laohu8.com/highlight/detail?id=2621065739","media":"TIPRANKS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2621065739?lang=en_us&edition=fundamental","pubTime":"2026-03-24 18:37","pubTimestamp":1774348644,"startTime":"0","endTime":"0","summary":"Aardvark Therapeutics, Inc. ( ($AARD) ) has shared an announcement. On March 23, 2026, Aardvark Therapeutics, Inc. entered into an equity distribut...","market":"nz","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tipranks_highlight","url":"https://www.tipranks.com/news/company-announcements/aardvark-therapeutics-establishes-150-million-equity-program?utm_source=itigerup.com&utm_medium=referral","rn_cache_url":null,"directOrigin":true},"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.tipranks.com/news/company-announcements/aardvark-therapeutics-establishes-150-million-equity-program?utm_source=itigerup.com&utm_medium=referral","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"tipranks_highlight","symbols":["BK4585","BK4588","EQR","BK4007","BK4215","AARD"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2621789063","title":"Aardvark Therapeutics Inc - Enters Equity Distribution Agreement With Piper Sandler on March 23, 2026 - SEC Filing","url":"https://stock-news.laohu8.com/highlight/detail?id=2621789063","media":"THOMSON REUTERS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2621789063?lang=en_us&edition=fundamental","pubTime":"2026-03-24 18:10","pubTimestamp":1774347027,"startTime":"0","endTime":"0","summary":null,"market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260324:nFWN40C03N:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"reuters_en_live","symbols":["AARD","BK4007"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2621063783","title":"Aardvark Therapeutics Inc - May Offer Shares up to $150 Mln Aggregate Offering Price - SEC Filing","url":"https://stock-news.laohu8.com/highlight/detail?id=2621063783","media":"THOMSON REUTERS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2621063783?lang=en_us&edition=fundamental","pubTime":"2026-03-24 18:10","pubTimestamp":1774347027,"startTime":"0","endTime":"0","summary":null,"market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260324:nFWN40C03N:2","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"reuters_en_live","symbols":["AARD","BK4007"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2621063186","title":"Aardvark Therapeutics signs equity distribution agreement for up to USD 150 million offering","url":"https://stock-news.laohu8.com/highlight/detail?id=2621063186","media":"Reuters","labels":["shareholding"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2621063186?lang=en_us&edition=fundamental","pubTime":"2026-03-24 18:02","pubTimestamp":1774346552,"startTime":"0","endTime":"0","summary":"Aardvark Therapeutics entered into an equity distribution agreement with Piper Sandler to sell shares of its common stock from time to time.The program allows sales of up to USD 150.0 million in aggregate offering price under the company’s shelf registration statement.Piper Sandler will receive a 3% commission on the gross sales price per share sold under the agreement.The company is not obligated to sell any shares under the arrangement.Disclaimer: This news brief was created by Public Technologies  using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Aardvark Therapeutics Inc. published the original content used to generate this news brief via EDGAR, the Electronic Data Gathering, Analysis, and Retrieval system operated by the U.S. Securities and Exchange Commission , on March 24, 2026, and is solely ","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":"ab6e84fb0542480d9cf75cb6a9fe5601","theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260324:nNDL5CrwhS:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"shareholding","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK4007","BK4127","AARD","PIPR","LU0053671581.USD"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2621087042","title":"Aardvark pauses two obesity drug trials as it reviews side effects","url":"https://stock-news.laohu8.com/highlight/detail?id=2621087042","media":"Reuters","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2621087042?lang=en_us&edition=fundamental","pubTime":"2026-03-24 05:52","pubTimestamp":1774302726,"startTime":"0","endTime":"0","summary":"March 23  - Aardvark Therapeutics AARD.O said on Monday it has voluntarily paused two mid-stage studies testing its experimental combination treatment for obesity as it reviews side effects associated with one of the drugs.The combination treatment, ARD-201, was being tested to induce weight loss and prevent weight regain among patients who have lost about 15% of body weight on the popular GLP-1 class of drugs, which includes Eli Lilly's LLY.N Zepbound and Novo Nordisk's NOVOb.CO Wegovy.ARD-201 is a combination of Aardvark's experimental drug, ARD-101, and Merck's diabetes drug MRK.N Januvia, chemically known as sitagliptin.ARD-101 is designed to trigger the release of multiple gut-peptide hormones, including GLP-1, to regulate hunger.Last month, the company identified heart-related side effects during safety monitoring of ARD-101 in a healthy-volunteer study. It then paused a late-stage trial testing ARD-101 in patients with a rare genetic disorder called Prader-Willi syndrome.Aardvar","market":"nz","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":"ab6e84fb0542480d9cf75cb6a9fe5601","theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260323:nL4N40B1W4:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["LU0985320562.USD","LU1551013342.USD","LLII","LU0106261372.USD","LU2756315318.SGD","LU0868494617.USD","SG9999018857.SGD","AARD","LU0477156953.USD","LU0203201768.USD","LU1037948897.HKD","LU2111349929.HKD","LU0225283273.USD","LU1720051108.HKD","LU1023059063.AUD","LU0708995401.HKD","LU2750360997.AUD","LU2746668461.USD","BK4534","IE00BK4W5M84.HKD","LU1868836757.USD","SG9999015341.SGD","LU2746668974.SGD","LU0861579265.USD","LU0353189763.USD","LU1066051498.USD","LU0130102774.USD","LU2357305700.SGD","LU2028103732.USD","LU2237443978.SGD","LU2468319806.SGD","LU1585245621.USD","LU2471134879.HKD","LU1989772840.SGD","LU2237443549.SGD","ELIS","LU0354030511.USD","LU0820562030.AUD","LU2237443382.USD","LU0070302665.USD","LU1571399168.USD","LU2324357040.USD","LU1291159041.SGD","IE00BN8TJ469.HKD","LU2750360641.GBP","SGXZ51526630.SGD","LU1934455863.HKD","LU2112291526.USD","LU0965509010.AUD","BK4588","LU0323591593.USD","SG9999001440.SGD","SG9999014880.SGD","LU0203347892.USD","LU0882574055.USD","LU2211815571.USD","LU1145028129.USD","IE0002141913.USD","SG9999014542.SGD","SG9999013999.USD","LU0238689110.USD","LU2237443895.HKD","SG9999015952.SGD","LU0097036916.USD","LU1934455194.USD","IE00BK4W5L77.USD","IE00BWXC8680.SGD","LU0098860793.USD","LU0158827781.USD","IE00BFSS7M15.SGD","LU0203345920.USD","BK4550","LU1323610961.USD","LU1548497426.USD","LU2491049909.HKD","SG9999014914.USD","LU0094547139.USD","LU2265009873.SGD","LU2602419157.SGD","LU0122379950.USD","LU1934455277.USD","LU0672654240.SGD","LU1116320901.HKD","BK4516","IE00BBT3K403.USD","LU1127390331.HKD","BK4599","LU0640476718.USD","SGXZ31699556.SGD","ELIL","SGXZ99366536.SGD","LU0432979614.USD","LU0354030438.USD","LU1551013425.SGD","LU1712237335.SGD","LU0823434583.USD","LU1280957306.USD","LU0471298777.SGD","LU0823416689.USD","GB00BDT5M118.USD","IE00B1BXHZ80.USD","IE00BJLML261.HKD","LU0882574139.USD","LU0320765059.SGD","LU0787776722.HKD","SG9999001176.SGD","BK4581","LU1061106388.HKD","LU2106854487.HKD","LU1366192091.USD","LU2237443622.USD","LU2491050071.SGD","LU1929549753.HKD","LU1162221912.USD","LU0130517989.USD","LU2756315664.SGD","IE00BKDWB100.SGD","LU0198837287.USD","LU2089283258.USD","LU0965509283.SGD","LU0211331839.USD","LU0265550359.USD","BK4007","LU0786609619.USD","LU0158827948.USD","LU1066051811.HKD","LU2125154935.USD","IE00BN29S564.USD","LU2237443465.HKD","LU0203202063.USD","SG9999014906.USD","IE00B775H168.HKD","LU0320765489.SGD","SG9999002224.SGD","LU2360032135.SGD","LU2456880835.USD","LU1804176565.USD","SG9999015358.SGD","LU1988902786.USD","LU2168564149.EUR","LU0109391861.USD","LU2361044865.SGD","SG9999018865.SGD","BK4585","LLYZ","LU2361044949.HKD","LU0980610538.SGD","LU2213496289.HKD","LU2471134796.USD","LU0943347566.SGD","LU1974910355.USD","SG9999015978.USD","LU0079474960.USD","LU0058720904.USD","LU1069344957.HKD","LU0265550946.USD","LU0256863811.USD","LU1064131342.USD","IE0004445239.USD","LU0320765646.SGD","SG9999001176.USD","LU0868494708.USD","LU0456855351.SGD","LU2023250330.USD","LU1093756325.SGD","LU1201861249.SGD","LU0689472784.USD","LU0683600562.USD","LU1623119135.USD","LU1868836591.USD","IE00BKPKM429.USD","IE00BSNM7G36.USD","IE0001KFT4U8.USD","LU0471298694.HKD","LU1232071149.USD","LU2264538146.SGD","LU2108987350.USD","LU1035775433.USD","LU0889565916.HKD","LU0234572021.USD","LU2471134523.USD","IE00BJT1NW94.SGD","IE00B4R5TH58.HKD","LU2237438978.USD","LU0096364046.USD","LU0210536198.USD","LU2462157665.USD","SG9999014559.SGD","LU2417539215.USD","LU0353189680.USD","LU0061475181.USD","LU0648001328.SGD","LU2023251221.USD","BK4559","LU0289739699.SGD","LU0466842654.USD","IE0009355771.USD","LU2089284900.SGD","LU2089984988.USD","LU2360106947.USD","SG9999014575.USD","LU2063271972.USD","LU1035773651.USD","LU0965508806.USD","LU1989772923.USD","LU1037948541.HKD","LU2023250843.SGD","IE00BLSP4239.USD","LU2896262040.SGD","SG9999017495.SGD","LU1917777945.USD","LU1941712348.USD","LU0208291251.USD","LU0385154629.USD","SG9999015945.SGD","SG9999014898.SGD","IE00B4JS1V06.HKD","LU1720051017.SGD","LU2491050154.USD","LU2552382215.SGD","SG9999002232.USD","LU0417517546.SGD","IE00BFSS8Q28.SGD","LU1116320737.USD","LU2361045086.USD","LU2087625088.SGD","SGXZ81514606.USD","LU2125154778.USD","LU2168563687.JPY","LU1093756168.USD","LU0964807845.USD","LU1699723380.USD","LU1983299246.USD","LU1868837136.USD","LU1989771016.USD","LU2271345857.HKD","LU0256863902.USD","IE00BFTCPJ56.SGD","IE00BJJMRZ35.SGD","IE0004445015.USD","IE000M9KFDE8.USD","LLYX","LU2168564495.EUR","LU2552382058.USD","LU0109394709.USD","LU1057294990.SGD","IE00BJJMRX11.SGD","IE00B2B36J28.USD","LU2461242641.AUD","LU1629891620.HKD","LU0266013472.USD","BK4533","IE00BJJMRY28.SGD","LU2168564065.EUR","LU2552382132.HKD","LU1814569148.SGD","LU1868836914.USD","LU2471134952.CNY","LU0114720955.EUR","LU1066051225.USD","LU0320765992.SGD","LU0316494557.USD","LU0820561818.USD","LU0823434740.USD","LU1267930730.SGD","LU0006306889.USD","IE0005OL40V9.USD","LU0965509101.SGD","LU2023250504.SGD","LU0820561909.HKD","LU1066053197.SGD","IE00B1XK9C88.USD","LU1941712264.USD","SG9999015986.USD","LU1868837300.USD","LU2236285917.USD","IE00B7KXQ091.USD","LU1430594728.SGD","SGXZ57979304.SGD","IE00BLSP4452.SGD","LU2168564222.USD","LU1069347547.HKD","LU0942090050.USD","SG9999014567.USD"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2621499087","title":"Aardvark Therapeutics Files $400 Million Mixed Shelf","url":"https://stock-news.laohu8.com/highlight/detail?id=2621499087","media":"MT Newswires Live","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2621499087?lang=en_us&edition=fundamental","pubTime":"2026-03-24 05:34","pubTimestamp":1774301669,"startTime":"0","endTime":"0","summary":"Aardvark Therapeutics  filed a shelf registration statement on Monday with the US Securities and Exchange Commission for the potential sale of up to $400 million in securities.The filing covers common and preferred stock, debt securities, warrants, rights, units, and depositary shares.Net proceeds will be used for general corporate purposes.","market":"sg","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":"f6f7c9f6a0174df79daf9f1dfd21f836","theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.mtnewswires.com/","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"mtnewswires_news","symbols":["AARD","BK4007"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2621087537","title":"Aardvark Therapeutics files $400M mixed securities shelf","url":"https://stock-news.laohu8.com/highlight/detail?id=2621087537","media":"TIPRANKS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2621087537?lang=en_us&edition=fundamental","pubTime":"2026-03-24 05:15","pubTimestamp":1774300511,"startTime":"0","endTime":"0","summary":"17:11 EDT Aardvark Therapeutics (AARD) files $400M mixed securities shelf Published first on TheFly – the ultimate source for real-time, market-mov...","market":"nz","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tipranks_highlight","url":"https://www.tipranks.com/news/the-fly/aardvark-therapeutics-files-400m-mixed-securities-shelf-thefly-news?utm_source=itigerup.com&utm_medium=referral","rn_cache_url":null,"directOrigin":true},"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.tipranks.com/news/the-fly/aardvark-therapeutics-files-400m-mixed-securities-shelf-thefly-news?utm_source=itigerup.com&utm_medium=referral","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"tipranks_highlight","symbols":["BK4007","AARD"],"isVideo":false,"video":null,"gpt_icon":0}],"pageSize":20,"totalPage":5,"pageCount":1,"totalSize":100,"code":"91000000","status":"200"}]}}